On February 22, 2023 Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, reported that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023 Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, reported that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision’s website in the Investors section under Events & Presentations on February 28, 2023: View Source An archived replay will be available for approximately 30 days following the event..

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision’s website in the Investors section under Events & Presentations on February 28, 2023: View Source An archived replay will be available for approximately 30 days following the event.